Clinical trials: Prognostic Biomarkers
Colorectal Neoplasms
Prospective Multicenter Cohort Study of Clinical and Molecular Biomarkers in Colorectal Cancer
This prospective, multicenter observational study aims to identify clinical and molecular biomarkers associated with treatment response, disease recurrence, progression, and survival in patients with colorectal cancer (CRC).
- Trial name
- NCT07913802
- Where
- 4 sites in Austria
- Volunteers
- 200 people
- Sponsor
- Vorarlberg Institute for Vascular Investigation and Treatment
Severe Sepsis or Septic Shock
Hepcidin: a Prognostic Marker of Morbidity and Mortality in Severe Sepsis?
Many biomarkers have been evaluated in sepsis, especially for prognostic purposes, but none has yet been shown to have sufficient sensitivity or specificity for routine use in clinical practice.
- Trial name
- HEP-SEPSIS (NCT03682003)
- Testing
- blood diagnostic tests
- Where
- France
- Volunteers
- 114 people
- Sponsor
- Rennes University Hospital
Alzheimer Disease
Validation of an Alzheimer's Disease Marker by Fecal Assay of Amyloid Peptides and Tau Proteins
Alzheimer's disease (AD) is the leading cause of dementia in humans, currently affecting almost one million people in France. It results from an irreversible degeneration of neurons responsible for a progressive decline in the…
- Trial name
- FecAlz (NCT06481878)
- Testing
- faecal analysis
- Where
- France
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- University Hospital, Grenoble
Sepsis
Red Cell Distribution Width Versus Presepsin (Soluble CD14) as a Prognostic Marker in Critically-ill Sepsis Patients
Presepsin (soluble CD14 subtype) is a novel marker with growing body of evidence supporting its accuracy and value for the diagnosis of sepsis. Patients with sepsis showed higher Prsepsin levels compared to those with SIRS.
- Trial name
- NCT03796715
- Testing
- Red Cell Distribution Width (RDW), Presepsin (sCD14-ST)
- Where
- Egypt
- Volunteers
- 200 people
- Sponsor
- Ain Shams University
Lupus Nephritis, Lupus Erythematosus, Systemic
Searching for Diagnostic/Prognostic Biomarkers in SLE With Renal Involvement by Proteomic Techniques
Objective: To search for potential biomarkers obtained by non-invasive methods (24-hour urine collection) that distinguish between patients diagnosed with systemic lupus erythematosus with or without renal involvement, patients…
- Trial name
- SLE (NCT03687138)
- Testing
- 24h urin sample
- Where
- Spain
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Natalia A. Rivera García
Blood Transfusion, Biochemical Marker
Red Cell Distribution Width (RDW) as a Prognostic Marker in ICU
The aim of this study is to verify if high values of RDW are useful prognostic marker for ICU mortality and 90-days mortality. Moreover, we will investigate the prognostic value of RDW in specific subgroup population with some…
- Trial name
- NCT02917811
- Where
- Italy
- Volunteers
- 250 people
- Sponsor
- Università degli Studi di Ferrara
Clear Cell Renal Cancer, Circulating Tumor Cells
Prospective Validation of Circulating Tumor Cells & Circulating Endothelial Cells as Biomarkers in Renal Cancer
Circulating tumor cells (CTCs) have prognostic value in several tumor types, and increasing evidence suggests that molecular characterization of CTCs can serve as a "liquid biopsy" to understand and address treatment resistance.
- Conditions
- Clear Cell Renal Cancer, Circulating Tumor Cells, Circulating Endothelial Cells, Prognostic Biomarkers
- Trial name
- NCT02499458
- Testing
- None- observational study
- Where
- Canada
- Volunteers
- 44 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Glioblastoma, Radiotherapy
Study of Prognostic Biomarkers of Survival at 6 Months for Patients Treated With Bevacizumab Glioblastomas in First Relapse After Failure of Radiochemotherapy
No predictive factors are known for the response to the bevacizumab anti-angiogenic molecule (Avastin) given in the event of relapse of glioblastoma (GBM) following radiochemotherapy.
- Conditions
- Glioblastoma, Radiotherapy, Chemotherapy
- Trial name
- SPECTROBEVA (NCT03144167)
- Testing
- Analysis of spectroscopic biomarkers of proliferation for six-month survival
- Where
- France
- Volunteers
- 170 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Cardiogenic Shock
CardShock Study and Registry
The aim of CardShock Study is to recognise significant prognostic factors in order to detect patients with increased mortality risk to which one could possibly direct more intensive treatments.
- Trial name
- CardShock (NCT01374867)
- Where
- Finland
- Volunteers
- 220 people
- Sponsor
- Helsinki University Central Hospital
Taurine in Cancer Colon
The Prospect of Using Serum Taurine Level as a Potential Biomarker for Early Detection of Colorectal Carcinoma and Its Correlation With Other Prognostic Markers
Serum taurine results in this study showed that, besides CRC biomarkers; it is most attractive, more precious and more accurate early biomarker for early detecting of any malignant change which may led to CRC by other mean it is…
- Trial name
- NCT04192539
- Testing
- Taurine
- Where
- Egypt
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Quality of Life
Recombinant Human Endostatin in Combination With XELOX Therapy in Patient With Advanced Colorectal Cancer.
To study safety and efficacy of intravenous pump of recombinant human endostatin combined with XELOX-treated and also investigate the potential value of CECs level for the prediction of PD and outcomes in patients with advanced…
- Trial name
- EXECC (NCT03577392)
- Testing
- oxaliplatin + capecitabine (XELOX chemotherapy), rebombniant human endostatin
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Sichuan Provincial People's Hospital
Heart Failure
Diagnostic, Risk Stratification and Prognostic Value of Novel Biomarkers in Patients With Heart Failure
The objective of this work is to investigate and then to sequence new biomarkers in the blood of patients with heart failure, and study their diagnostic, risk stratification and prognostic value.
- Trial name
- NCT03727828
- Testing
- Patients with heart failure
- Where
- China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Shanghai 10th People's Hospital
Acute GVH Disease
Biomarkers for Acute Graft-versus-host Disease
Validation of already described biomarkers on acute GVHD prediction and severity Fecal calprotectin and alpha 1 anti-trypsin, plasmatic RER3a, IL-8, Elafin, TNFaR1, IL-2R alpha, HGF
- Trial name
- PLASMA-INCA (NCT02254798)
- Testing
- no intervention
- Where
- 2 sites in France
- Volunteers
- 315 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Melanoma, Melanoma in Situ
BioMEL- Diagnostic and Prognostic Factors in Melanoma.
The investigators' hypothesis is that cutaneous melanoma, melanoma in situ, dysplastic nevi and benign nevi all differ in not only clinical characteristics but also molecular and genotypic characteristics.
- Conditions
- Melanoma, Melanoma in Situ, Dysplastic Nevi, Mole (Dermatology)
- Trial name
- BioMEL (NCT05446155)
- Testing
- Imaging
- Where
- 4 sites in Sweden
- Volunteers
- 2,000 people
- Sponsor
- Region Skane
Sarcoma, Ewing
The Prognostic Value of Serum Biomarkers in Ewing's Sarcoma
Extraction of laboratory data from blood tests prior to surgical and chemotherapy and other histological, clinical and instrumental data related to the patient's history from the digitized medical Digitized medical records and…
- Trial name
- NCT05100368
- Testing
- patients
- Where
- Italy
- Volunteers
- 1,000 people
- Sponsor
- Istituto Ortopedico Rizzoli
Hypoxic-Ischemic Encephalopathy, Asphyxia Perinatal
Identification of a Pool of miRNA to Improve Early Management of Perinatal Asphyxia and Hypoxic Ischemic Encephalopathy
Hypoxic-ischemic encephalopathy is the most common cause of neurological damage in the neonatal period. It has an incidence of about 1.5-2.5% of livebirths in developed countries.
- Trial name
- NCT05986994
- Testing
- Metabolic acidosis, microRNA, Hypothermia
- Where
- 2 sites in Italy
- Volunteers
- 45 people
- Sponsor
- Ospedale Buon Consiglio Fatebenefratelli
Oral Squamous Cell Carcinoma (OSCC), Periodontal Disease
Discovery and Validation of Biomarkers for Periodontitis, Dental Caries and Oral Squamous Cell Carcinoma
The goal of this observational study is to develop better ways to detect and predict major oral diseases, including oral cancer, gum disease, and tooth decay.
- Conditions
- Oral Squamous Cell Carcinoma (OSCC), Periodontal Disease, Dental Caries
- Trial name
- NCT07745803
- Testing
- Step 1 and 2 periodontal therapy according to the EFP clinical practice guidelines, Dental filling with or without root canal treatment, Oral cancer surgical resection including extension, dissection and reconstruction with adjunctive radiation, chemotherapy and/or biological treatments per international guidelines,
- Where
- China
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Chondrosarcomas, Cartilage Tumours
Diagnostic and Therapeutic Targets in Cartilaginous Tumours
This study, "Finding new diagnostic and therapeutic targets in cartilaginous tumours," focuses on improving the diagnosis, prognostic stratification, and treatment options for chondroid tumours, particularly chondrosarcoma.
- Trial name
- NCT07315542
- Testing
- Tumour tissue analysis, Molecular validation, Liquid biopsy analysis
- Where
- Czechia
- Volunteers
- 300 people
- Sponsor
- St. Anne's University Hospital Brno, Czech Republic
Wild-type ATTR Amyloidosis, Amyloidosis Cardiac
ATTR Amyloid Cardiomyopathy: Characterization of Extracellular Vesicles as Potential Disease Stratifiers and Prognostic Biomarkers
This study explores whether extracellular vesicles (EVs) tiny particles released into the bloodstream by cells can serve as early and minimally invasive biomarkers for transthyretin amyloid cardiomyopathy (ATTR-CM).
- Conditions
- Wild-type ATTR Amyloidosis, Amyloidosis Cardiac, Amyloidosis, Hereditary, Amyloidosis Transthyretin
- Trial name
- EV-ATTR (NCT07314268)
- Where
- Brazil
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo General Hospital
Lysosomal Storage Diseases, Gaucher Disease
Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher Disease
International, multicenter, epidemiological study to demonstrate the correlation and predictive value of lyso-Gb1 concentration with the clinical severity of naïve, initially non-ERT/SRT Gaucher disease type 1 and during the…
- Conditions
- Lysosomal Storage Diseases, Gaucher Disease, Sphingolipidoses
- Trial name
- LYSO-PROOF (NCT02416661)
- Where
- 8 sites in Albania, Greece and 5 more
- Volunteers
- 299 people
- Sponsor
- CENTOGENE GmbH Rostock